We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+14.17%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$883M
AUM Growth
+$301M
Cap. Flow
+$204M
Cap. Flow %
23.13%
Top 10 Hldgs %
65.86%
Holding
75
New
21
Increased
22
Reduced
4
Closed
17

Top Buys

Rank Stock Value
1
ITRM
Iterum Therapeutics
ITRM
+$20.8M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$16.7M
3
AGN
Allergan plc
AGN
+$16.4M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$15.4M
5
CELG
Celgene Corp
CELG
+$15.3M

Top Sells

Rank Stock Value
1
NCNA
NuCana
NCNA
+$98.5M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$16.5M
3
APLS
Apellis Pharmaceuticals
APLS
+$6.8M
4
ATYR
aTyr Pharma
ATYR
+$4.95M
5
BMY icon
Bristol-Myers Squibb
BMY
+$951K

Sector Composition

Rank Sector Weight
1 Healthcare 81.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$165M 18.69%
2,479,514
– –
OBSV
2
DELISTED
ObsEva SA Ordinary Shares
OBSV
$71.9M 8.15%
4,749,623
– –
NTRA icon
3
Natera
NTRA
$37.5B
$58.4M 6.61%
3,100,560
– –
MRUS
4
DELISTED
Merus
MRUS
$44.6M 5.06%
1,961,039
– –
CHRS icon
5
Coherus Oncology
CHRS
$217M
$40.5M 4.59%
2,893,221
– –
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$39.8M 4.51%
481,270
– –
BOLD
7
DELISTED
Audentes Therapeutics, Inc
BOLD
$35.7M 4.04%
933,640
-446,663
-32% -$16.5M
ACRS icon
8
Aclaris Therapeutics
ACRS
$730M
$30.7M 3.48%
1,539,480
– –
ITRM
9
DELISTED
Iterum Therapeutics
ITRM
$18.8M 2.13%
+115,101
New +$20.8M
AGN
10
DELISTED
Allergan plc
AGN
$18.6M 2.11%
111,550
+102,171
+1,089% +$16.4M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$17.5M 1.98%
140,752
+131,626
+1,442% +$15.4M
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$4.83B
$16M 1.81%
+922,700
New +$16.7M
CELG
13
DELISTED
Celgene Corp
CELG
$14.6M 1.66%
+184,399
New +$15.3M
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$13.5M 1.53%
615,802
-295,950
-32% -$6.8M
NCNA
15
NuCana
NCNA
$5.37M
$12.7M 1.44%
133
-800
-86% -$98.5M
CRSP icon
16
PUT
CRISPR Therapeutics
CRSP
$4.58B
$11.8M 1.33%
+200,000
New +$11.4M
AZN icon
17
AstraZeneca
AZN
$263B
$11.6M 1.31%
164,900
+153,984
+1,411% +$11.1M
AMRN
18
Amarin Corp
AMRN
$284M
$10.3M 1.16%
166,079
– –
AIMT
19
DELISTED
Aimmune Therapeutics
AIMT
$10.1M 1.14%
375,044
+354,736
+1,747% +$10.9M
HRTX icon
20
Heron Therapeutics
HRTX
$86.3M
$10M 1.14%
258,585
+228,452
+758% +$7.27M
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$8.96M 1.02%
+106,817
New +$7.82M
GWPH
22
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.8M 1%
63,070
+59,433
+1,634% +$8.44M
BLUE
23
DELISTED
bluebird bio
BLUE
$8.69M 0.98%
+4,275
New +$9.74M
ADMS
24
DELISTED
Adamas Pharmaceuticals
ADMS
$7.32M 0.83%
283,398
+267,192
+1,649% +$7.4M
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$680M
$6.43M 0.73%
227,273
+216,976
+2,107% +$7.72M
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2018 Portfolio in Review

As of Q2 2018, Sofinnova Investments held 75 positions worth $883M, up 52% from $582M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments deployed $204M of net new capital in Q2 2018, opening 21 new positions and adding to 22 existing holdings. Its largest new stake was Iterum Therapeutics: 115,101 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was NuCana, an estimated $98.5M trimmed.

  • Sofinnova Investments's largest Q2 2018 buy was Iterum Therapeutics: 115,101 shares worth $18.8M.
  • Sofinnova Investments added most to Allergan plc in Q2 2018, an estimated $16.4M increase.
  • Sofinnova Investments's biggest Q2 2018 reduction was NuCana, cutting an estimated $98.5M.
  • Sofinnova Investments fully exited aTyr Pharma in Q2 2018, selling an estimated $4.95M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $883M portfolio in Q2 2018.
  • Sofinnova Investments opened 21 new positions and closed 17 in Q2 2018.
  • Sofinnova Investments's portfolio value rose 52% quarter-over-quarter to $883M.

Based on Sofinnova Investments's 13F filing for Q2 2018, filed 14 Aug 2018.